APOE and atherosclerosis: The administration of teneligliptin, a DPP-4 inhibitor, attenuated atherosclerosis progression in apolipoprotein E (ApoE) knockout mice by alleviating inflammation and oxidative stress in both the vasculature and PVAT [145].